Pfizer announces EC grants conditional marketing authorization for Elrexfio

Pfizer announced the European Commission, or EC, has granted conditional marketing authorization for Elrexfio. Elrexfio is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Elrexfio is an off-the-shelf (ready-to-use) B-cell maturation antigen-CD3-directed bispecific antibody immunotherapy that induces deep and durable responses, with a manageable tolerability profile as well as convenient subcutaneous dosing.